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Introduction
The main limitation to a better knowledge of Autoinflam-
matory diseases is related to the extreme fragmentation of
the diagnosed cases that are spread over different centers
and countries. The general aim of the Eurofever Project
(agreement n 2007332, EAHC) is to build an international
registry on Autoinflammatory diseases.
Objectives
To evaluate the number of patients enrolled in the registry
in the first 36 months after starting the enrolment.
Methods
A web-based registry collecting baseline and cross-sec-
tional clinical information on Autoinflammatory diseases
is available in the member area of the PRINTO web-site
(http://www.printo.it). The registry is open to all pediatric
and adult Centers with a specific interest in Autoinflam-
matory diseases. The following monogenic autoinflamma-
tory diseases were considered: Familial Mediterranean
Fever (FMF), Cryopyrin-associated periodic syndromes
(CAPS), TNF receptor-associated periodic syndrome
(TRAPS), mevalonate kinase deficiency (MKD), Blau
syndrome, pyogenic arthritis, pioderma and acne (PAPA)
syndrome, deficiency of IL-1 receptor antagonist (DIRA),
NLRP12-mediated periodic fever. Information on CRMO,
Behçet’s disease, PFAPA and undefined periodic fevers
were also collected.
Results
2721 patients, from 221 centers in 56 countries, have
been enrolled in the registry during the first 36 months.
Baseline demographic data (country of residence, disease
onset, disease duration, mutations, family history ect)
from all patients are now available. In 2213 (81%)
complete information on clinical manifestations and
responses to treatments is also available. The disease
distribution of enrolled patients is: FMF 787 (621 with
complete clinical data); TRAPS 237 (211 with complete
clinical data); CAPS 207 (186 with complete clinical
data); MKD 153 (133 with complete clinical data); Blau
syndrome 62 (21 with complete clinical data); PAPA 19
(18 with complete clinical data); NLRP-12 mediated per-
iodic fever 8 (6 with complete clinical data); DIRA and
Majeed 3 and 2 patients, respectively (all with complete
clinical data). Among multifactorial autoinflammatory
diseases: PFAPA 564 (402 with complete clinical data);
CRMO 392 (370 with complete clinical data); pediatric
Behçet disease 84 (68 with complete clinical data) and
205 patients with undefined periodic fever (174 with
complete clinical data).
Conclusion
A large registry of patients with Autoinflammatory dis-
eases is available and the enrolment is still ongoing. In
the next months novel inherited autoinflammatory
diseases (CANDLE, DITRA) will be included and data




1for PRINTO and Eurofever Project, Genoa, Italy. 2Gaslini Institute, Genoa, Italy.
1for PRINTO and Eurofever Project, Genoa, Italy
Full list of author information is available at the end of the article
Federici et al. Pediatric Rheumatology 2013, 11(Suppl 2):P327
http://www.ped-rheum.com/content/11/S2/P327
© 2013 Federici et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P327
Cite this article as: Federici et al.: PReS-FINAL-2337: The eurofever
registry: 3 years of enrollment. Pediatric Rheumatology 2013 11(Suppl 2):
P327.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Federici et al. Pediatric Rheumatology 2013, 11(Suppl 2):P327
http://www.ped-rheum.com/content/11/S2/P327
Page 2 of 2
